

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-22. (Cancelled)

23. (Amended) A CXC chemokine receptor 4 (CXCR4) agonist peptide comprising:

a) a N-terminal sequence homologous to ~~an amino acids 1-14 of native stromal cell derived factor-1 (SDF-1) N-terminal sequence,~~ the N-terminal sequence having the formula

K[P or D]VS[L or D]SYR[C or A or F or H or W or Y]P[C or F or W or Y or H or A]RFF

b) a C-terminal sequence homologous to ~~an amino acids 55-67 of native SDF-1 C-terminal sequence or to a MIP-1alpha sequence,~~ the C-terminal sequence having an internal cyclic amide bridge formed between a carboxylic acid side chain on a first amino acid residue and an amine side chain on a second amino acid residue, the C-terminal sequence having the following formula wherein the residues that may form the internal cyclic amide bridge are identified by an *,

L[K or O]*WIQ[E or D]*YLE[K or O]*ALN

and,

c) a ~~peptide-spacer~~ sequence linking the N-terminal sequence to the C-terminal sequence, wherein the ~~peptide-spacer~~ sequence ~~linking the N-terminal sequence to the C-terminal~~ comprises ~~naturally-occurring amino acids, non-naturally-occurring amino acids, or both naturally-occurring amino acids and non-naturally-occurring amino acids~~ is of the formula G₁₋₄ or (CH₂)₁₋₄.

Claims 24-26 (Cancelled)

27. (Amended) The CXCR4 agonist of ~~any one of claims claim~~ claim 23 to 26 where the C-

termini is an acid or an amide.







28. (Amended) The CXCR4 agonist peptide of any one of claims 23 to 27 wherein the peptide is selected from the group consisting of polypeptides having sequence of SEQ ID NO: ~~12 to 27~~ 20 to 25.
29. (Amended) The CXCR4 agonist of claim 28 wherein the peptide is SEQ ID NO: ~~13~~ 22 (CTCE0022) or 23 (CTCE0021).
30. (New) The CXCR4 agonist of claim 23, wherein the agonist is selected from the group consisting of the following, wherein n=1-4 and PEG is a polyethylene glycol moiety:


□
K[D-P]VLSYRCPCRFFGGGGLKWIQEYLEKALN-NH₂


□
K[D-P]VLSYRCPCRFF-(CH₂)_n-LKWIQEYLEKALN-NH₂


□
[PEG-Lys]PVLSYRCPCRFFGGGGLKWIQEYLEKALN-NH₂



□
[PEG-Lys]PVS[D-L]SYRCPCRFF-(CH₂)_n-LKWIQEYLEKALN-NH₂
with PEG MW =500-20000

















with PEG(Polyethyleneglycol chain) MW=500-20000






with PEG(Polyethyleneglycol chain) MW=500-20000













31. (New) The CXCR4 agonist of claim 23, wherein the agonist is selected from the group consisting of the following, wherein $n=1-4$ and PEG is a polyethylene glycol moiety:

















32. (New) The CXCR4 agonist of claim 23, wherein the agonist is H-[Ala⁹-Phe¹¹]-SDF-(1-14)-4Gly-cyclo(Lys⁵⁶-Glu⁶⁰)-SDF-(55-67)-NH₂, having the sequence

